evernorth glp-1 Navigating demand, cost, and sustainability in healthcare Cigna doubles down on GLP-1

The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.

Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated

Obesity has further been associated with higher disease activity and reduced time to flare

She came to Ro for the same reason thousands of others do: we offer convenient access to GLP-1 treatment, high-quality care, and support that actually fits into her life

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

But while theyre effective, many users experience mild skin irritation, redness, or tenderness at the injection site